Clinical Trials Logo

Alcohol-related Liver Disease clinical trials

View clinical trials related to Alcohol-related Liver Disease.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06305624 Not yet recruiting - Clinical trials for Alcohol Use Disorder

Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease

IMPACT-ALD
Start date: June 2024
Phase: N/A
Study type: Interventional

This protocol describes a randomized controlled trial testing the effectiveness and implementability of the CHESS Health Connections smartphone application among patients with alcohol-associated liver disease (ALD) at two medical centers in Michigan and Wisconsin, in two types of clinics: general hepatology and multidisciplinary that offers care for advanced ALD alongside co-located, integrated mental health and substance abuse treatment. The long-term goal of this and future work is to prevent disease progression and promote healthy behaviors by improving the rate of abstinence among patients with ALD earlier in the course of their disease. 298 participants will be enrolled and can expect to be on study for up to 6 months.

NCT ID: NCT06269510 Not yet recruiting - Liver Diseases Clinical Trials

Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients

Start date: April 2025
Phase: N/A
Study type: Interventional

The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.

NCT ID: NCT05623150 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome

CHALNA2
Start date: December 1, 2022
Phase:
Study type: Observational

The aim is to determine the metabolic factors, host immune factors, and medical imaging data associated with the development of HepatoCellular Carcinoma (HCC) in patients with alcohol-related liver disease or dysmetabolic steatosis/Non-Alcoholic SteatoHepatitis. The investigators will include patients with and without cirrhosis in order to identify early molecular mechanisms involved in the development of HCC especially in non-cirrhotic patients.